Conversion from twice-daily tacrolimus to an extended release formulation in stable kidney transplant recipients: 2-year follow-up results of a single centre
Autor(a) principal: | |
---|---|
Data de Publicação: | 2015 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692015000100007 |
Resumo: | Introduction: Calcineurin inhibitors are currently considered the cornerstone of maintenance immunosuppression in renal transplantation. The extended release formulation of tacrolimus (ER-TAC) was developed to improve drug adherence in these patients. The long-term safety and efficacy of the conversion from the twice-daily tacrolimus to the ER-TAC is still undetermined. Subjects and Methods: Retrospective registry-based single centre study including all renal transplant recipients converted from TAC twice-daily to the ER-TAC on a 1: 1 mg basis. We collected biometric data, induction regimens, acute rejection episodes and death. Variables of interest [serum creatinine, blood urea nitrogen, fasting glucose, urinalysis, haemoglobin, TAC dose (mg/kg) and TAC trough levels (ng/ml)] were registered at conversion and 1, 6, 12 months and at last follow-up post-conversion. Results: We analysed 127 patients, 71.9 % male, mean age at conversion (± SD) was 49.8 ± 13.6 years. Conversion occurred at 4.10 ± 3.83 years after transplant and our mean follow-up time was 2.56 ± 0.55 years. TAC trough levels (ng/ml) progressively decreased from pre-conversion to the following stages (pre-conversion: 7.41 ± 2.61 vs. last followup: 5.04 ± 1.86, p < 0.001) but no significant dose adjustments were necessary for attaining predetermined target levels. Renal function remained stable and there were no significant differences in glucose metabolism pre and post conversion. No significant adverse effects were verified. There were no episodes of acute rejection throughout the follow-up. Conclusions: The conversion to ER-TAC ensured effective immunosuppression over a follow-up of 2 years suggesting that this formulation is an excellent alternative to the conventional one |
id |
RCAP_4e7e3971d38f8b29a1b3c2aa4653d6aa |
---|---|
oai_identifier_str |
oai:scielo:S0872-01692015000100007 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Conversion from twice-daily tacrolimus to an extended release formulation in stable kidney transplant recipients: 2-year follow-up results of a single centreConversionextended releaseimmunosuppressionrenal transplantationtacrolimusIntroduction: Calcineurin inhibitors are currently considered the cornerstone of maintenance immunosuppression in renal transplantation. The extended release formulation of tacrolimus (ER-TAC) was developed to improve drug adherence in these patients. The long-term safety and efficacy of the conversion from the twice-daily tacrolimus to the ER-TAC is still undetermined. Subjects and Methods: Retrospective registry-based single centre study including all renal transplant recipients converted from TAC twice-daily to the ER-TAC on a 1: 1 mg basis. We collected biometric data, induction regimens, acute rejection episodes and death. Variables of interest [serum creatinine, blood urea nitrogen, fasting glucose, urinalysis, haemoglobin, TAC dose (mg/kg) and TAC trough levels (ng/ml)] were registered at conversion and 1, 6, 12 months and at last follow-up post-conversion. Results: We analysed 127 patients, 71.9 % male, mean age at conversion (± SD) was 49.8 ± 13.6 years. Conversion occurred at 4.10 ± 3.83 years after transplant and our mean follow-up time was 2.56 ± 0.55 years. TAC trough levels (ng/ml) progressively decreased from pre-conversion to the following stages (pre-conversion: 7.41 ± 2.61 vs. last followup: 5.04 ± 1.86, p < 0.001) but no significant dose adjustments were necessary for attaining predetermined target levels. Renal function remained stable and there were no significant differences in glucose metabolism pre and post conversion. No significant adverse effects were verified. There were no episodes of acute rejection throughout the follow-up. Conclusions: The conversion to ER-TAC ensured effective immunosuppression over a follow-up of 2 years suggesting that this formulation is an excellent alternative to the conventional oneSociedade Portuguesa de Nefrologia2015-03-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692015000100007Portuguese Journal of Nephrology & Hypertension v.29 n.1 2015reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692015000100007Rodrigues,LuísMacário,FernandoPego,CátiaNeves,MartaRomaozinho,CatarinaSantos,LidiaAlves,RuiSa,HelenaMota,AlfredoCampos,Márioinfo:eu-repo/semantics/openAccess2024-02-06T17:04:47Zoai:scielo:S0872-01692015000100007Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:18:54.022823Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Conversion from twice-daily tacrolimus to an extended release formulation in stable kidney transplant recipients: 2-year follow-up results of a single centre |
title |
Conversion from twice-daily tacrolimus to an extended release formulation in stable kidney transplant recipients: 2-year follow-up results of a single centre |
spellingShingle |
Conversion from twice-daily tacrolimus to an extended release formulation in stable kidney transplant recipients: 2-year follow-up results of a single centre Rodrigues,Luís Conversion extended release immunosuppression renal transplantation tacrolimus |
title_short |
Conversion from twice-daily tacrolimus to an extended release formulation in stable kidney transplant recipients: 2-year follow-up results of a single centre |
title_full |
Conversion from twice-daily tacrolimus to an extended release formulation in stable kidney transplant recipients: 2-year follow-up results of a single centre |
title_fullStr |
Conversion from twice-daily tacrolimus to an extended release formulation in stable kidney transplant recipients: 2-year follow-up results of a single centre |
title_full_unstemmed |
Conversion from twice-daily tacrolimus to an extended release formulation in stable kidney transplant recipients: 2-year follow-up results of a single centre |
title_sort |
Conversion from twice-daily tacrolimus to an extended release formulation in stable kidney transplant recipients: 2-year follow-up results of a single centre |
author |
Rodrigues,Luís |
author_facet |
Rodrigues,Luís Macário,Fernando Pego,Cátia Neves,Marta Romaozinho,Catarina Santos,Lidia Alves,Rui Sa,Helena Mota,Alfredo Campos,Mário |
author_role |
author |
author2 |
Macário,Fernando Pego,Cátia Neves,Marta Romaozinho,Catarina Santos,Lidia Alves,Rui Sa,Helena Mota,Alfredo Campos,Mário |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Rodrigues,Luís Macário,Fernando Pego,Cátia Neves,Marta Romaozinho,Catarina Santos,Lidia Alves,Rui Sa,Helena Mota,Alfredo Campos,Mário |
dc.subject.por.fl_str_mv |
Conversion extended release immunosuppression renal transplantation tacrolimus |
topic |
Conversion extended release immunosuppression renal transplantation tacrolimus |
description |
Introduction: Calcineurin inhibitors are currently considered the cornerstone of maintenance immunosuppression in renal transplantation. The extended release formulation of tacrolimus (ER-TAC) was developed to improve drug adherence in these patients. The long-term safety and efficacy of the conversion from the twice-daily tacrolimus to the ER-TAC is still undetermined. Subjects and Methods: Retrospective registry-based single centre study including all renal transplant recipients converted from TAC twice-daily to the ER-TAC on a 1: 1 mg basis. We collected biometric data, induction regimens, acute rejection episodes and death. Variables of interest [serum creatinine, blood urea nitrogen, fasting glucose, urinalysis, haemoglobin, TAC dose (mg/kg) and TAC trough levels (ng/ml)] were registered at conversion and 1, 6, 12 months and at last follow-up post-conversion. Results: We analysed 127 patients, 71.9 % male, mean age at conversion (± SD) was 49.8 ± 13.6 years. Conversion occurred at 4.10 ± 3.83 years after transplant and our mean follow-up time was 2.56 ± 0.55 years. TAC trough levels (ng/ml) progressively decreased from pre-conversion to the following stages (pre-conversion: 7.41 ± 2.61 vs. last followup: 5.04 ± 1.86, p < 0.001) but no significant dose adjustments were necessary for attaining predetermined target levels. Renal function remained stable and there were no significant differences in glucose metabolism pre and post conversion. No significant adverse effects were verified. There were no episodes of acute rejection throughout the follow-up. Conclusions: The conversion to ER-TAC ensured effective immunosuppression over a follow-up of 2 years suggesting that this formulation is an excellent alternative to the conventional one |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015-03-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692015000100007 |
url |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692015000100007 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692015000100007 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Nefrologia |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Nefrologia |
dc.source.none.fl_str_mv |
Portuguese Journal of Nephrology & Hypertension v.29 n.1 2015 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137279073058816 |